Last reviewed · How we verify
D-serine solution
D-serine acts as a co-agonist at the N-methyl-D-aspartate (NMDA) receptor by binding to the glycine site, enhancing glutamatergic neurotransmission.
D-serine acts as a co-agonist at the N-methyl-D-aspartate (NMDA) receptor by binding to the glycine site, enhancing glutamatergic neurotransmission. Used for Schizophrenia (negative and cognitive symptoms), Cognitive impairment associated with schizophrenia.
At a glance
| Generic name | D-serine solution |
|---|---|
| Sponsor | University of Minnesota |
| Drug class | NMDA receptor co-agonist |
| Target | NMDA receptor (glycine site) |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | Phase 3 |
Mechanism of action
D-serine is an endogenous amino acid that functions as a neuromodulator in the central nervous system. It binds to the glycine-binding site on NMDA receptors, which are required for full receptor activation alongside glutamate. By increasing D-serine availability, the drug potentiates NMDA receptor signaling, which is thought to enhance synaptic plasticity and cognitive function, particularly in conditions characterized by hypofunction of this pathway.
Approved indications
- Schizophrenia (negative and cognitive symptoms)
- Cognitive impairment associated with schizophrenia
Common side effects
- Headache
- Nausea
- Dizziness
- Fatigue
Key clinical trials
- Cognitive Strategies in Early Psychosis 2 (PHASE3)
- Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers (PHASE1)
- TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders (PHASE3)
- Sequential Therapy for the Treatment of Severe Bipolar Depression. (PHASE2)
- Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) (PHASE3)
- Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery (PHASE2)
- A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-serine solution CI brief — competitive landscape report
- D-serine solution updates RSS · CI watch RSS
- University of Minnesota portfolio CI